Nov 14, 2025 04:30PM IceCure Medical receives Nasdaq bid price deficiency notice

Nov 3, 2025 08:33AM IceCure study shows combined therapy achieves 92% lung cancer survival rate

Oct 7, 2025 06:39AM IceCure Medical Ltd. (ICCM) PT Raised to $2.50 at H.C. Wainwright

Oct 3, 2025 12:21PM IceCure receives FDA approval for breast cancer cryoablation device

Sep 22, 2025 08:32AM IceCure Medical presents clinical data at CIRSE meeting in Barcelona

Sep 15, 2025 08:31AM IceCure receives Israel approval for XSense cryoablation system

Aug 15, 2025 06:53AM IceCure Medical Ltd. (ICCM) PT Lowered to $2 at H.C. Wainwright

Aug 13, 2025 01:58PM IceCure Medical Ltd. (ICCM) PT Lowered to $2.77 at Brookline Capital Markets

Aug 13, 2025 08:42AM IceCure Medical Ltd (ICCM) Tops Q2 EPS by 18c

Jul 29, 2025 09:02AM IceCure completes $10 million rights offering, twice oversubscribed

Jul 10, 2025 08:02AM IceCure Medical starts $10 million rights offering

Jul 3, 2025 08:34AM IceCure Medical Ltd (ICCM) Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jun 25, 2025 09:24AM IceCure Medical Ltd (ICCM) Announces Record Date for Rights Offering for Up to $10 Million

Jun 16, 2025 07:18AM IceCure Medical Ltd (ICCM) has determined not to pursue, at this time, the public offering

Jun 9, 2025 08:32AM IceCure (ICCM) receives notice of allowance in U.S. Patent and Trademark Office for Cryogen Flow Control

May 30, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on IceCure Medical Ltd. (ICCM)

May 28, 2025 08:33AM IceCure Medical Ltd (ICCM) Tops Q1 EPS by 14c

May 6, 2025 08:33AM IceCure Medical Ltd (ICCM) Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense Cryoablation

Apr 30, 2025 08:30AM IceCure Medical Ltd (ICCM) Announces Positive FDA Development

Mar 28, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on IceCure Medical Ltd. (ICCM)

Mar 24, 2025 08:32AM IceCure's (ICCM) ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 20, 2025 08:31AM IceCure Medical Ltd (ICCM) Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense Cryoablation in Early-Stage Breast Cancer

Mar 17, 2025 08:31AM IceCure Medical Ltd (ICCM) Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Feb 24, 2025 08:34AM IceCure Medical Ltd (ICCM) files for approval of XSense system

Jan 27, 2025 08:41AM IceCure Medical Ltd (ICCM) Files for Regulatory Approval of ProSense Cryoablation System in China

Jan 6, 2025 08:31AM IceCure Medical Ltd (ICCM) Regains Nasdaq Compliance

Jan 3, 2025 08:30AM European Patent Office Issues Intention to Grant Notice to IceCure (ICCM) for its Next-Generation Cryoablation Technology

Nov 29, 2024 06:35AM H.C. Wainwright Reiterates Buy Rating on IceCure Medical Ltd. (ICCM)

Oct 21, 2024 08:32AM IceCure Medical Ltd (ICCM) Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System

Sep 24, 2024 08:16AM IceCure's (ICCM) ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal

Sep 13, 2024 06:47AM H.C. Wainwright Reiterates Buy Rating on IceCure Medical Ltd. (ICCM)

Sep 12, 2024 08:01AM IceCure Medical (ICCM) Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense Scheduled for November 7, 2024

Aug 28, 2024 08:31AM IceCure Medical Ltd (ICCM): USPTO Grants Notice of Allowance for Additional Patent on Novel Cryogenic Pump Technology

Aug 21, 2024 06:42AM IceCure Medical Ltd. (ICCM) PT Lowered to $2.50 at H.C. Wainwright

Aug 7, 2024 08:30AM IceCure Medical Ltd (ICCM) Announces Positive Data from the Largest Multi-Institutional Study of its Kind

Jul 22, 2024 08:35AM IceCure Medical (ICCM) announces key findings from three clinical studies of ProSense in treatment of breast cancer were presented

Jul 19, 2024 04:30PM IceCure Medical Ltd (ICCM) Receives Nasdaq Non-compliance Notice

Jul 9, 2024 08:32AM IceCure Medical (ICCM): European Study Provides More Evidence Supporting ProSense is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer

Jul 1, 2024 08:30AM IceCure Medical Ltd (ICCM) Granted FDA Regulatory Clearance for Next-Gen XSense Cryoablation System